WallStreetZenWallStreetZen

NASDAQ: LEXX
Lexaria Bioscience Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their LEXX stock forecasts and price targets.

Forecast return on equity

Is LEXX forecast to generate an efficient return?

Company
N/A
Industry
19.78%
Market
168.97%

Forecast return on assets

Is LEXX forecast to generate an efficient return on assets?

Company
N/A
Industry
23.77%

LEXX earnings per share forecast

What is LEXX's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$4.74
Avg 2 year Forecast
-$4.28

LEXX revenue forecast

What is LEXX's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$1.4M+637.63%
Avg 2 year Forecast
$1.6M+733.51%
Avg 3 year Forecast
$71.6M+36,802.06%
LEXX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

LEXX revenue growth forecast

How is LEXX forecast to perform vs Biotechnology companies and vs the US market?

Company
576.11%
Industry
30.7%
Market
14.37%
LEXX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
LEXX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

LEXX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LEXX$3.20N/AN/A
QCLS$0.64N/AN/A
EVGN$0.40N/AN/A
AIM$0.18$7.00+3,788.89%Buy
LNAI$1.12N/AN/A
View Top Biotech Stocks

Lexaria Bioscience Stock Forecast FAQ

What is LEXX's earnings growth forecast for 2027-2028?

(NASDAQ: LEXX) Lexaria Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.33%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.57%.

Lexaria Bioscience's earnings in 2026 is -$7,732,026.On average, 3 Wall Street analysts forecast LEXX's earnings for 2027 to be -$7,837,789, with the lowest LEXX earnings forecast at -$7,530,424, and the highest LEXX earnings forecast at -$8,068,312.

In 2028, LEXX is forecast to generate -$7,079,293 in earnings, with the lowest earnings forecast at -$6,801,674 and the highest earnings forecast at -$7,287,507.

If you're new to stock investing, here's how to buy Lexaria Bioscience stock.

What is LEXX's revenue growth forecast for 2027-2029?

(NASDAQ: LEXX) Lexaria Bioscience's forecast annual revenue growth rate of 576.11% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.37%.

Lexaria Bioscience's revenue in 2026 is $194,000.On average, 3 Wall Street analysts forecast LEXX's revenue for 2027 to be $2,364,722, with the lowest LEXX revenue forecast at $2,272,182, and the highest LEXX revenue forecast at $2,434,127. On average, 3 Wall Street analysts forecast LEXX's revenue for 2028 to be $2,672,086, with the lowest LEXX revenue forecast at $2,566,326, and the highest LEXX revenue forecast at $2,749,753.

In 2029, LEXX is forecast to generate $118,302,189 in revenue, with the lowest revenue forecast at $113,661,980 and the highest revenue forecast at $121,780,693.

What is LEXX's forecast return on assets (ROA) for 2027-2029?

(NASDAQ: LEXX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 23.77%.

What is LEXX's Earnings Per Share (EPS) forecast for 2027-2028?

(NASDAQ: LEXX) Lexaria Bioscience's current Earnings Per Share (EPS) is -$5.05. On average, analysts forecast that LEXX's EPS will be -$4.74 for 2027, with the lowest EPS forecast at -$4.56, and the highest EPS forecast at -$4.88. In 2028, LEXX's EPS is forecast to hit -$4.28 (min: -$4.12, max: -$4.41).

What is LEXX's forecast return on equity (ROE) for 2027-2029?

(NASDAQ: LEXX) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.